ACTRN12619000669190招募中2 期
A randomised, double-blind, single-centre, placebo-controlled trial of low-dose clonidine infusion to improve sleep in postoperative patients in the High Dependency Unit
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Post-operative elective surgical patients admitted to the RBWH Elective Surgery High Dependency Unit (ESHDU).
- •2. ESHDU doctor (registrar or consultant) agrees to the subject’s participation.
排除标准
- •1. Age less than 18 years.
- •2. Pregnancy or breastfeeding.
- •3. Patients admitted to ICU (instead of ESHDU).
- •4. ICU research coordinators not be available for enrolment (e.g. after 20:00) or completion of study assessments (Saturday morning – i.e. Friday admissions).
- •5. Patients who are expected to be discharged home directly from ESHDU the day after surgery.
- •6. Patients who take clonidine as a regular medication prior to surgery.
- •7. Patients prescribed an a2 agonist (e.g. clonidine or dexmedetomidine) during the current admission (e.g. as premedication, perioperatively as an adjunct to anaesthesia, or as a PCA/PCEA adjunct)... except:
- •* IV or oral clonidine up to maximum total dose of 1 mcg/kg administered either intraoperatively or in the Post Anaesthesia Care Unit will be permitted.
- •8. Advanced dementia (in the premorbid state requiring professional nursing care)
- •9. The patient has previously been enrolled in a clinical trial of a sedative, antipsychotic or anti-delirium medication during this admission.
- •10. Severe bradyarrhythmia resulting from either sick sinus syndrome or AV block of second or third degree.
- •11. Known allergy to alpha2-agonists including clonidine or dexmedetomidine.
- •12. End-stage kidney disease or use of dialysis (prior to or during current admission).
- •13. Comorbidities that will prevent or interfere with sleep measurement via the FitBit Alta HR, i.e. disease or condition such that wearing the device is either not possible (e.g. bilateral amputee, burns, loss of skin, etc), or will not be effective due to abnormal limb movement (e.g. quadriplegia, severe motor neuron disease, etc).
研究者
相似试验
进行中（未招募）
1 期
A clinical trial assessing the effect of a new antibiotic (Solithromycin) on inflammation in the small air passages of patients with chronic obstructive pulmonary disease.Chronic Obstructive Pulmonary Disease.MedDRA version: 18.0 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-003077-42-GBImperial College, London6
进行中（未招募）
1 期
A single-centre, randomised, double-blind, placebo-controlled, cross-over study to assess the efficacy of a 5-day, once daily 10-mg PBF-680 oral administration course to attenuate allergen bronchoprovocation-induced late asthmatic responses (LAR) in asthmatic patients controlled on low-to-medium dose inhaled corticosteroid maintenance monotherapy and inhaled short-acting beta-2 agonist as rescue bronchodilator.Treatment for asthma.MedDRA version: 18.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-001957-34-ESPalobiofarma S.L.16
已完成
不适用
A randomized, single-center, double-blind, placebo-controlled, 2-way cross-over, single oral administration trial to evaluate blood-borne biomarker candidates to predict NOP receptor activation using GRT6010 as NOP receptor agonist in healthy human subjects.neuropathic pain10034606NL-OMON37607Grunenthal24
进行中（未招募）
不适用
A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformiEUCTR2006-001219-31-DEovartis Pharma Services AG22
进行中（未招募）
不适用
A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 diabetesType II DiabetesEUCTR2006-001218-34-SEovartis Pharma Services AG28